Trials / Recruiting
RecruitingNCT06958211
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 550 (estimated)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruxolitinib Cream | Ruxolitinib cream applied topically to the affected area as a thin film twice daily. |
| DRUG | Vehicle Cream | Matching vehicle cream applied topically to the affected area as a thin film twice daily. |
Timeline
- Start date
- 2025-06-12
- Primary completion
- 2026-10-09
- Completion
- 2027-07-11
- First posted
- 2025-05-06
- Last updated
- 2026-04-08
Locations
107 sites across 9 countries: United States, Belgium, Bulgaria, Canada, France, Germany, Netherlands, Poland, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06958211. Inclusion in this directory is not an endorsement.